Imunon Ownership
| IMNN Stock | USD 0.81 0.12 17.39% |
Shares in Circulation | First Issued 1996-09-30 | Previous Quarter 9.4 M | Current Value 14.4 M | Avarage Shares Outstanding 1.7 M | Quarterly Volatility 4.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Imunon |
Imunon Stock Ownership Analysis
About 15.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Imunon Inc recorded a loss per share of 1.91. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 1st of March 2022. Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey. Imunon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. To learn more about Imunon Inc call Stacy Lindborg at 609 896 9100 or check out https://imunon.com.Besides selling stocks to institutional investors, Imunon also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Imunon's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Imunon's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Imunon Quarterly Liabilities And Stockholders Equity |
|
Only 1.09% of Imunon Inc are currently held by insiders. Unlike Imunon's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Imunon's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Imunon's insider trades
Imunon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Imunon is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Imunon Inc backward and forwards among themselves. Imunon's institutional investor refers to the entity that pools money to purchase Imunon's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Group One Trading, Lp | 2024-06-30 | 129 | Bank Of America Corp | 2024-06-30 | 77.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 66.0 | Royal Bank Of Canada | 2024-06-30 | 2.0 | Game Plan Financial Advisors, Llc | 2024-06-30 | 2.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 2.0 | Hanson Mcclain Inc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 74.7 K | Renaissance Technologies Corp | 2024-09-30 | 63.6 K |
Imunon Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Imunon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Imunon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Imunon insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
| 0.64 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.85 | VALN | Valneva SE ADR | PairCorr |
| 0.81 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Imunon Stock
| 0.59 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.52 | RNXT | RenovoRx | PairCorr |
| 0.43 | KZR | Kezar Life Sciences | PairCorr |
| 0.39 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.